Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA accepted the new drug application resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
In other news, BMS and partner Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use adopted a positive opinion on Eliquis (apixaban) for the prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation and one or more risk factors for stroke
Pfizer Inc., of New York, said the World Health Organization granted an expansion to the prequalification of Pfizer's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to include adults 50 and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes in the vaccine
Pfizer Inc., of New York, said the European Commission granted marketing authorization for Inlyta (axitinib) in adult patients with advanced renal cell carcinoma after failure of prior treatment with Sutent (sunitinib) or a cytokine
Pfizer Inc., of New York, and Mylan Inc., of Pittsburgh, said they signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan
Pfizer Inc., of New York, reported that the FDA extended the action date for its new drug application for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA), by three months
Pfizer Inc., of New York, will pay more than $60 million to resolve Department of Justice (DOJ) and SEC investigations into improper payments made by two of its subsidiaries outside the U.S. Pfizer H.C.P. Corp
Novartis AG, of Basel, Switzerland, said the FDA approved mTOR inhibitor Afinitor (everolimus) for use in combination with Aromasin (exemestane, Pfizer Inc.) to treat certain postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer...Pfizer Inc., of New York, said it received a positive opinion on Xalkori (crizotinib) from the Committee for Medicinal Products for Human Use of the European Medicines Agency
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA issued a complete response letter (CRL) on the new drug application for Eliquis (apixaban) for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation
Pfizer Inc., of New York, received FDA approval for the use of Lyrica (pregabalin) capsules CV in the management of neuropathic pain associated with spinal cord injury
Pfizer Inc., of New York, and Cold Spring Harbor Laboratory established a research collaboration to develop a human short hairpin RNA library to silence gene expression through the process of RNA interference and to identify new therapeutic targets in cancer
Pfizer Inc., of New York, presented reports of studies on Lyrica (pregabalin) at the American Pain Society meeting in Honolulu, including an exploratory study, using functional magnetic resonance imaging (fMRI), showing that Lyrica decreased connectivity between various parts of the brain involved in pain processing in fibromyalgia patients
Pfizer Canada Inc., of Kirkland, Quebec, part of Pfizer Inc., launched Xyntha Solofuse in Canada to prevent and control hemorrhagic episodes in patients with hemophilia A. The preloaded device delivers Xyntha (recombinant Factor VIII) by intravenous infusion after reconstitution of a freeze-dried powder
Antares Pharma Inc., of Ewing, N.J., said development partner Teva Pharmaceutical Industries Ltd., of Jerusalem, entered into a settlement agreement with Pfizer Inc
Pfizer Inc., of New York, is facing a lawsuit alleging negligence and other allegations claiming that the firm failed to warn the medical community that antidepressant Zoloft (sertraline) carried a risk of congenital birth defects when taken during pregnancy
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA accepted the new drug application resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation